Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.55 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.55 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.52 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.51 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.51 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.51 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5667184 | 1.00 | FAAH (0.62) | FAAHMEN1KMT2AMAPK1NOD1 | |
| SCHEMBL17204243 | 1.00 | FAAH (0.62) | FAAHMEN1KMT2AMAPK1NOD1 | |
| SCHEMBL543568 | 1.00 | FAAH (0.62) | FAAHMEN1KMT2AMAPK1NOD1 | |
| SCHEMBL17203963 | 1.00 | FAAH (0.62) | FAAHMEN1KMT2AMAPK1NOD1 | |
| SCHEMBL8823482 | 1.00 | FAAH (0.62) | FAAHMEN1KMT2AMAPK1NOD1 | |
| SCHEMBL7268170 | 1.00 | FAAH (0.62) | FAAHMEN1KMT2AMAPK1NOD1 | |
| SCHEMBL25196976 | 1.00 | FAAH (0.62) | FAAHMEN1KMT2AMAPK1NOD1 | |
| SCHEMBL7269318 | 1.00 | FAAH (0.62) | FAAHMEN1KMT2AMAPK1NOD1 | |
| SCHEMBL11047281 | 1.00 | FAAH (0.62) | FAAHMEN1KMT2AMAPK1NOD1 | |
| SCHEMBL338364 | 1.00 | FAAH (0.62) | FAAHMEN1KMT2AMAPK1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250073673-A1 | NANONETS FOR REMOVAL OF CONTAMINANTS FROM AQUEOUS SOLUTIONS, KITS THEREFOR AND METHODS OF THEIR USE | CARBONET NANOTECHNOLOGIES INC. (CA) | 2025-03-06 | — | — | US | claimed |
| EP-4414063-A1 | NANONETS FOR REMOVAL OF CONTAMINANTS FROM AQUEOUS SOLUTIONS, KITS THEREFOR AND METHODS OF THEIR USE | Carbonet Nanotechnologies Inc. (CA) | 2024-08-14 | — | — | EP | claimed |
| US-20210087250-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2021-03-25 | — | — | US | claimed |
| EP-3006045-B3 | Pharmaceutical formulations for the oral delivery of peptide or protein drugs | CYPRUMED GMBH (AT) | 2021-03-17 | — | — | EP | claimed |
| EP-3773475-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | Cyprumed GmbH (AT) | 2021-02-17 | — | — | EP | claimed |
| WO-2019193204-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2019-10-10 | — | — | WO | claimed |
| EP-3204045-B1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2018-12-05 | — | — | EP | claimed |
| US-20180280481-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | CYPRUMED GMBH (AT) | 2018-10-04 | — | — | US | claimed |
| WO-2018065634-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE NASAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2018-04-12 | — | — | WO | claimed |
| US-20170304195-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2017-10-26 | — | — | US | claimed |
| EP-3204045-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | Cyprumed GmbH (AT) | 2017-08-16 | — | — | EP | claimed |
| WO-2017060500-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | CYPRUMED GMBH (AT) | 2017-04-13 | — | — | WO | claimed |
| EP-3006045-B1 | Pharmaceutical formulations for the oral delivery of peptide or protein drugs | CYPRUMED GMBH (AT) | 2017-04-12 | — | — | EP | claimed |
| WO-2016055550-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2016-04-14 | — | — | WO | claimed |
| EP-3006045-A1 | Pharmaceutical formulations for the oral delivery of peptide or protein drugs | Cyprumed GmbH (AT) | 2016-04-13 | — | — | EP | claimed |
| US-20140056953-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | NOVO NORDISK A/S (DK) | 2014-02-27 | — | — | US | claimed |
| EP-2696847-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | Novo Nordisk A/S (DK) | 2014-02-19 | — | — | EP | claimed |
| WO-2012140155-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | NOVO NORDISK A/S (DK) | 2012-10-18 | — | — | WO | claimed |
| EP-4414063-B1 | NANONETS FOR REMOVAL OF CONTAMINANTS FROM AQUEOUS SOLUTIONS, KITS THEREFOR AND METHODS OF THEIR USE | CARBONET NANOTECHNOLOGIES INC (CA) | 2026-04-15 | — | — | EP | disclosed |
| US-4442090-A | ACYLATED AMINO ACID | KYOTO YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1984-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304195-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | SLC30A5, SLC30A6, SON | FAAH 4519/4885MEN1 1008/4885KMT2A 4043/4885 |
| US-20180280481-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | SLC30A5, SLC39A11, SLC30A6 | FAAH 4365/4885MEN1 463/4885KMT2A 3506/4885 |
| US-20210087250-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | VIP, PTMS, VASP | FAAH 3710/4885MEN1 1112/4885KMT2A 2222/4885 |
| US-20140056953-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | SLC27A1, SLC27A2, FABP2 | FAAH 63/4885MEN1 4654/4885KMT2A 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.